Summary
Theranos claimed to run hundreds of medical tests from a single finger-prick of blood. The technology never worked. The company raised nearly a billion dollars and was valued at $9B before the Wall Street Journal exposed the fraud in 2015. By 2018 the SEC had charged Holmes; by 2022 she was convicted.
What killed it
Fraud at the core: the headline product never functioned, but the company kept running tests on conventional Siemens machines and lying to investors, regulators, and patients. When journalism and regulators caught up, the inspection trail was undeniable. Investor pressure for a multi-billion-dollar valuation made every honest off-ramp look like a step down — so the lie kept growing until it broke.
Lessons
- A board of generals is not a board of biotech experts.
- “We can’t show you the device working” is a complete answer.
- Regulatory capture is finite — eventually someone audits.